Emmanuel Akporiaye

Dr. Emmanuel Akporiaye, Ph.D., is the Founder and CEO of Veana Therapeutics. He has over 30 years of immunotherapy experience specializing in the modulation of the tumor microenvironment to improve cancer treatment. Dr. Akporiaye founded the company in 2012, as a spin-off from the Earle A. Chiles Research Institute of the Providence Cancer Center.

Dr. Akporiaye is a Fulbright Senior Scholar and a Professor Emeritus in the Dept. of Microbiology and Immunology, Univ. of Arizona. He received his Ph.D. in Microbiology from the University of New Mexico, Albuquerque in 1983, and his M.S. in Biology from New Mexico Highlands University, Las Vegas, New Mexico in 1978. His B.Sc. in Biochemistry was awarded by the University of Ife, Ile-Ife, Nigeria in 1973.

Prior to founding Veana Therapeutics, Dr. Akporiaye was Division Chief of Experimental Biology and Scientific Career Development at Sidra Medical and Research Center, Doha, Qatar. Prior to joining Sidra, Dr. Akporiaye was Chief of The Laboratory of Tumor Immunology and Therapeutics at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon.

Dr. Akporiaye has published over 70 peer-reviewed papers. He has served on several national and regional Scientific Review Committees and Advisory Boards including the National Institute of Health (NIH), Susan Komen Foundation, Department of Defense Breast Cancer Research Program, Fred Hutchinson Cancer Research Center, Ovarian Cancer SPORE Program and Legere Pharmaceuticals, Inc. He is a permanent member of the NIH Transition to Independence Initial Review Group for the advancement of basic and clinical scientists to independent careers. He holds the positions of Adjunct Full Member at the Earle A. Chiles Research Institute at Providence Cancer Center and Legacy Health.